Cytori Therapeutics (CYTX) Tops Q4 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results
April 1, 2019 8:05 AM EDTStrategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM
Letter of intent for ATI-0918 filed with EMEA
SAN DIEGO, April 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (Cytori or the Company) today announced its fourth quarter and year-end 2018 financial results and provided updates on corporate activities. Also announced was a transaction to divest... More
